Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
Synlogic, Inc. (Nasdaq: SYBX) has initiated a Phase 1 clinical trial for its oral therapy, SYNB1353, aimed at treating homocystinuria (HCU). The first healthy volunteer has been dosed, marking a significant milestone in advancing Synlogic's pipeline. SYNB1353 is engineered to lower homocysteine levels, addressing a pressing medical need as current treatment options are limited. Results from this study are expected by the end of 2022. This development reflects the efficiency of Synlogic's Synthetic Biotic platform and contributes to three anticipated clinical readouts for the year.
- Phase 1 trial for SYNB1353 initiated, indicating progress in development.
- SYNB1353 targets a significant unmet medical need in HCU treatment.
- Expected data readouts by the end of 2022 could attract investor interest.
- Current treatment options for HCU remain limited.
- Potential risks associated with clinical trial outcomes impacting future development.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year
Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform
CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today that it has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 designed to consume methionine for the potential treatment of homocystinuria (HCU).
“We are delighted to continue to advance our pipeline of programs with today’s announcement, a notable milestone as we continue towards three expected clinical readouts in 2022, and a reflection of the productivity of the Synthetic Biotic platform,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “Given the particularly great need for new treatment options for those living with HCU, we look forward to sharing data from this study by the end of this year.”
SYNB1353 is a drug candidate designed to provide a safe, orally administered, non-systemically absorbed treatment to consume methionine, with the goal of lowering homocysteine levels in patients with HCU, thereby lowering the risk of serious and debilitating complications. HCU is an inherited disorder characterized by high levels of homocysteine and risks including thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. Treatment options for HCU are currently limited due to efficacy and tolerability. SYNB1353 is an engineered strain of the probiotic bacteria E. coli Nissle (EcN) which consumes methionine within the gastrointestinal tract, preventing methionine absorption and conversion to homocysteine in plasma. It is the first drug candidate developed through a research collaboration between Synlogic and Ginkgo and the first investigational medicine developed on Ginkgo's platform to enter the clinic. In 2021, Synlogic shared preclinical data for SYNB1353 that demonstrated the lowering of blood homocysteine levels in non-human primates and mouse models. Synlogic expects to share results from the Phase 1 study of SYNB1353 in healthy volunteers by the end of 2022.
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. In addition to its clinical programs, Synlogic has research collaborations with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks on additional undisclosed preclinical assets. For additional information visit www.synlogictx.com.
About SYNB1353
SYNB1353 is a novel orally administered, non-systemically absorbed drug candidate designed to consume methionine in the gastrointestinal tract thereby lowering homocysteine levels in patients with homocystinuria (HCU). HCU is an inherited disorder characterized by high levels of homocysteine and risks including thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. Treatment options for HCU are currently limited due to efficacy and tolerability. Synlogic holds worldwide development and commercialization rights to SYNB1353 and is expected to report Phase 1 data in healthy volunteers in H2 2022.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," “look forward,” "estimate," "expect," "intend," on track,” "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
Media Contact:
Bill Berry
Berry & Company Public Relations
212-253-8881; bberry@berrypr.com
Investor Contact:
Andrew Funderburk
Kendall Investor Relations
617-914-0008; afunderburk@kendallir.com
FAQ
What is SYNB1353 and its purpose in treating HCU?
When will the results from the SYNB1353 Phase 1 study be available?
What are the potential risks associated with SYNB1353?
How does SYNB1353 work in the body?
